The company said it might start making new products in Romania, using its 30 percent production capacity from the former Sicomed factory. Sanofi Aventis has also said it is planning to start exporting the Gerovital brand. The company has finished integrating Zentiva and has structured the business into four divisions, original RX, generic RX, OTC and vaccines. It has reported a 10 percent market share by value and 16 percent by sales volume, based on information from Cegedim. “The group had totals sales of RON 730 million between August 2008 and August 2009,” said company officials. Although the businesses have been integrated, Sanofi Aventis and Zentiva will continue to operate as distinct firms, as well as corporate brands within the Sanofi Aventis group, said Dan Ivan, country manager of Sanofi Aventis Romania and president of the administration board at Zentiva.